CIAM
ABVC icon

Caitong International Asset Management’s ABVC BioPharma ABVC Stock Holding History

Caitong International Asset Management’s Portfolio ABVC Stock Details ABVC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9 Buy
+6
New +$7 ﹤0.01% 2652

Other funds holding ABVC

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Caitong International Asset Management's ABVC Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in ABVC BioPharma (ABVC) in Q2 2026: 6 shares worth $9. The stake represents ﹤0.01% of the portfolio and ranks #2652 among its holdings.

15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

  • Caitong International Asset Management held 6 shares of ABVC BioPharma worth $9 as of Q2 2026.
  • ABVC BioPharma was a new Caitong International Asset Management position in Q2 2026.
  • ABVC BioPharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2652 holding.
  • 15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.